Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as MeMuRu-OKA (study vacc), MeMuRu-OKA (study vac), MeMuRu-OKA (study vaccine)
MeMuRu-OKA · 3 trials · 4 indications
| Name | Type | Description |
|---|---|---|
| MeMuRu-OKA (study vaccine) | BIOLOGICAL | - |
| MeMuRu-OKA (study vac) | BIOLOGICAL | - |
| MMR, Varicella vacc (control) | BIOLOGICAL | - |
| MeMuRu-OKA (study vacc) | BIOLOGICAL | - |
Inclusion Criteria: * Children must be healthy and have a birth weight \> 2000 g to participate Exclusion Criteria: * confirmed or suspected tuberculosis, immunosuppressive (including HIV) conditions, neurological disorders, history of allergic disease or reaction, major congenital defects, chron...
MeMuRu-OKA is an investigational combination vaccine developed by GSK plc for protection against measles, mumps, rubella, and varicella. It is designed to deliver all four antigens in a single product, and it has been studied in healthy infants and young children from about 11 to 15 months of age.
MeMuRu-OKA is being developed for immunization against measles, mumps, rubella, and varicella in young children. Clinical studies enrolled healthy volunteers starting at 11 to 15 months of age, evaluating the combined vaccine against a regimen of Priorix given together with Varilrix.
MeMuRu-OKA is developed by GSK plc, which trades under the ticker GSK. GSK sponsored the clinical studies of the vaccine, including the Phase 2 and Phase 3 trials conducted in France, Germany, Italy, and Canada.
MeMuRu-OKA has reached Phase 3 clinical development. One Phase 3 study, NCT00351923, evaluated the vaccine using two different administration routes in Germany. Two earlier Phase 2 studies, NCT00353288 and NCT00352898, compared it with Priorix given with Varilrix. It is investigational and not approved.
MeMuRu-OKA has been studied in three completed trials. NCT00353288 and NCT00352898 were Phase 2 immunogenicity and safety studies comparing it with Priorix plus Varilrix, and NCT00351923 was a Phase 3 study of two administration routes. All three trials have completed.
Yes. MeMuRu-OKA is also referred to as MeMuRu-OKA (study vacc), MeMuRu-OKA (study vac), and MeMuRu-OKA (study vaccine). These are alternate labels for the same GSK combination vaccine against measles, mumps, rubella, and varicella, so searches using those names refer to this asset.